Cypherpunk Technologies (NASDAQ:CYPH) Downgraded by Wall Street Zen to Sell

Wall Street Zen lowered shares of Cypherpunk Technologies (NASDAQ:CYPH) from a hold rating to a sell rating in a research note issued to investors on Saturday morning.

Separately, Weiss Ratings upgraded shares of Cypherpunk Technologies from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, April 22nd. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Cypherpunk Technologies Stock Down 9.6%

Shares of NASDAQ CYPH opened at $1.09 on Friday. The firm has a market cap of $105.98 million, a price-to-earnings ratio of -54.22 and a beta of -0.09. Cypherpunk Technologies has a 52-week low of $0.23 and a 52-week high of $3.70. The business’s 50 day moving average is $0.84 and its two-hundred day moving average is $0.99.

Cypherpunk Technologies (NASDAQ:CYPH) last posted its quarterly earnings results on Monday, May 18th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.42).

Institutional Investors Weigh In On Cypherpunk Technologies

Institutional investors and hedge funds have recently made changes to their positions in the business. Texas Capital Bank Wealth Management Services Inc purchased a new stake in shares of Cypherpunk Technologies in the fourth quarter valued at about $121,000. Geode Capital Management LLC purchased a new stake in shares of Cypherpunk Technologies in the fourth quarter valued at about $615,000. Acadian Asset Management LLC raised its holdings in shares of Cypherpunk Technologies by 470.4% in the first quarter. Acadian Asset Management LLC now owns 1,280,531 shares of the company’s stock valued at $389,000 after buying an additional 1,056,047 shares during the last quarter. State Street Corp purchased a new stake in shares of Cypherpunk Technologies in the fourth quarter valued at about $163,000. Finally, HighTower Advisors LLC purchased a new position in Cypherpunk Technologies during the fourth quarter worth about $59,000. 30.46% of the stock is owned by hedge funds and other institutional investors.

Cypherpunk Technologies Company Profile

Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.

DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.